169 related articles for article (PubMed ID: 30140975)
1. Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?
Gao Y; Hennig S; Barras M
Clin Pharmacokinet; 2019 Mar; 58(3):389-399. PubMed ID: 30140975
[TBL] [Abstract][Full Text] [Related]
2. Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.
Barras MA; Serisier D; Hennig S; Jess K; Norris RL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6698-6702. PubMed ID: 27572411
[TBL] [Abstract][Full Text] [Related]
3. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.
Hennig S; Holthouse F; Staatz CE
Clin Pharmacokinet; 2015 Apr; 54(4):409-21. PubMed ID: 25403847
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis.
Burgard M; Sandaradura I; van Hal SJ; Stacey S; Hennig S
Clin Pharmacokinet; 2018 Aug; 57(8):1017-1027. PubMed ID: 29134570
[TBL] [Abstract][Full Text] [Related]
5. Bayesian Forecasting for Intravenous Tobramycin Dosing in Adults With Cystic Fibrosis Using One Versus Two Serum Concentrations in a Dosing Interval.
Drennan PG; Thoma Y; Barry L; Matthey J; Sivam S; van Hal SJ
Ther Drug Monit; 2021 Aug; 43(4):505-511. PubMed ID: 33941739
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
[TBL] [Abstract][Full Text] [Related]
7. Area under the curve achievement of once daily tobramycin in children with cystic fibrosis during clinical care.
Brockmeyer JM; Wise RT; Burgener EB; Milla C; Frymoyer A
Pediatr Pulmonol; 2020 Dec; 55(12):3343-3350. PubMed ID: 32827334
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Relationship between FEV
Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
Massie J; Cranswick N
J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
Lam W; Tjon J; Seto W; Dekker A; Wong C; Atenafu E; Bitnun A; Waters V; Yau Y; Solomon M; Ratjen F
J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy.
Nezic L; Derungs A; Bruggisser M; Tschudin-Sutter S; Krähenbühl S; Haschke M
Eur J Clin Pharmacol; 2014 Jul; 70(7):829-37. PubMed ID: 24756148
[TBL] [Abstract][Full Text] [Related]
12. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
Hennig S; Norris R; Kirkpatrick CM
Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
[TBL] [Abstract][Full Text] [Related]
13. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.
Stenbit AE; Bullington WM; Heh JL; Flume PA
J Cyst Fibros; 2013 Jul; 12(4):403-6. PubMed ID: 23266092
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm.
Touw DJ; Vinks AA; Neef C
Pharm World Sci; 1997 Jun; 19(3):142-51. PubMed ID: 9259030
[TBL] [Abstract][Full Text] [Related]
15. Is there a multinational consensus of tobramycin prescribing and monitoring for cystic fibrosis? Survey of current therapeutic drug monitoring practices in USA/Canada, UK/Ireland, and Australia/New Zealand.
Larcombe R; Coulthard K; Eaton V; Tai A; Reuter S; Ward M
Eur J Hosp Pharm; 2024 Jun; 31(4):301-306. PubMed ID: 36600520
[TBL] [Abstract][Full Text] [Related]
16. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring.
de Hoog M; Mouton JW; Schoemaker RC; Verduin CM; van den Anker JN
Clin Pharmacol Ther; 2002 May; 71(5):349-58. PubMed ID: 12011820
[TBL] [Abstract][Full Text] [Related]
17. Determination of tobramycin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
Madsen V; Lind A; Rasmussen M; Coulthard K
J Cyst Fibros; 2004 Dec; 3(4):249-51. PubMed ID: 15698943
[TBL] [Abstract][Full Text] [Related]
18. Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis: an Update.
Gao Y; Barras M; Hennig S
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263058
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis.
Bates RD; Nahata MC; Jones JW; McCoy K; Young G; Cox S; Barson WJ
Chest; 1997 Nov; 112(5):1208-13. PubMed ID: 9367459
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis.
Sherwin CM; Zobell JT; Stockmann C; McCrory BE; Wisdom M; Young DC; Olson J; Ampofo K; Spigarelli MG
J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):71-9. PubMed ID: 24395072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
